Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

Restless Legs Syndrome (RLS) Clinical Trial

Official title:

A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study Assessing the Effect of 600 mg Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01411124
• Other study ID #: 114111
• Status: Completed
• Phase: Phase 1
• First received: July 28, 2011
• Last updated: July 15, 2013
• Start date: June 2011
• Est. completion date: October 2011

Study information

• Verified date: November 2011
• Source: XenoPort, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.

Description:

proportional systemic gabapentin exposure over a wide dose range. This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance. Subjects will receive each of 3 treatments in a randomized order: GEn 600 mg, placebo and placebo/diphenhydramine 50 mg. Each treatment period will consist of 6 days, with subjects being dosed at approximately 5 pm on each dosing day. The placebo /diphenhydramine treatment will consist of placebo on Days 1-4 and 6 and 50 mg diphenhydramine on Day 5. Placebo will be administered on Day 6 in all treatment periods to ensure washout of drug prior to the start of the next treatment period. Simulated driving performance will be assessed at baseline (prior to randomization) and on Day 5 in the evening (7-9 pm) and on Day 6 between7-9 am and between 11am-1pm for each treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures

• Male or female between 18 and 65 years of age, at the time of signing the informed consent.

• A female subject is eligible to participate if she is of Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation at least 6 months previously or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/mL and estradiol < 40 pg/mL (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit is completed.

• Body weight > 50 kg and Body Mass Index (BMI) within the range 19 - 30 kg/m2 (inclusive)

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

• QTcB < 450 msec

• Creatinine clearance (CrCl) >80 mL/min. CrCl is estimated using the equation of Cockcroft and Gault. See study procedure manual for details on creatinine clearance calculations.

• AST, ALT, alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

• Currently a licensed, experienced driver who drives at least 3 times a week for the past 3 years and with visual acuity assessed by the investigator as being adequate for driving

• Able to complete a 1 hour simulated driving test and demonstrate satisfactory driving skills at screening

Exclusion Criteria:

• The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines

• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening

• A positive test for HIV antibody

• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits.

• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety

• History of sensitivity to gabapentin, DPH or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation

• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period

• Pregnant females as determined by positive serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing

• Lactating females

• Unwillingness or inability to follow the procedures outlined in the protocol

• The subject has a screening heart rate <50 or >100 bpm or a systolic blood pressure >140 or <100 mmHg or a diastolic blood pressure >90 or <60 mmHg in the semi-supine position after at least 3 minutes of rest.

• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening

• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease

• History of seizures other than febrile seizures as a child

• Subjects who have received any medications known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration, in the opinion of the Sponsor or Investigator

• Subjects with a creatine kinase (CK) value of greater than the upper limit of normal that is not explainable by recent strenuous exercise and the value does not return within normal range upon retest

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

• Subject is mentally or legally incapacitated

• Subjects with a sleep disorder e.g. sleep apnea, narcolepsy or primary insomnia

• Shift workers who are not on normal day/night sleep cycles

• Subjects with a history of closed angle glaucoma, urinary retention or other conditions for which DPH is contra-indicated

• Has active suicidal plan/intent or has had active suicidal thoughts in the past 6 months. Has history of suicide attempt in the last 2 years or more than 1 lifetime suicide attempt

• Subjects who have consumed an average of > 5 cups of caffeinated beverages per day within 20 days of the screening visit

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Restless Legs Syndrome
• Restless Legs Syndrome (RLS)

Intervention

Drug:
• gabapentin enacarbil
600 mg investigational compound
• diphenhydramine
50 mg active comparator
• placebo
placebo

Locations

Country	Name	City	State
United States	GSK Investigational Site	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
XenoPort, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lane performance Variability	change from baseline in lane position variability	From Day-1 baseline to end of treatment. Participants will be followed for the duration of the clinic visit an average of 3 weeks.	No
Secondary	Change in Speed Variability	Change from baseline in speed variability	from baseline to end of treatment Participants will be followed for the duration of the clinic visit an average of 3 weeks	No
Secondary	number of simulated crashes	number of simulated crashes	on Days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 week	No
Secondary	Visual Analog Scale	Pre driving alterness measured by the Visual analog scale	Baseline to end of treatment. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	No
Secondary	Visual analog scale on post driving alertness	Post driving alterness measured by visual alterness scale	baseline to days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	No
Secondary	Visual Analog scale of the difference between pre and post driving alertness	difference between pre and post driving alertness	baseline to days 5 and 6. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	No
Secondary	Incidents of Adverse events	safety and tolerability from baseline to end of study	baseline to end of study. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	Yes
Secondary	Plasma concentrations of gabapentin	Plasma concentration of gabapentin on completion of driving test	Day 5. The subjects will be followed for the duration of the clinic visit an average of 3 weeks	No